Overview

Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the study are to evaluate the efficacy and safety of three doses of MCC-257 in patients with mild to moderate diabetic polyneuropathy
Phase:
Phase 2
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation